{"slug":"t-cell-engager-target","tag":"t-cell-engager-target","variants":["t-cell-engager-target"],"description":"No description yet","count":6,"kinds":{"target":6},"related":[{"slug":"car-t-target","tag":"car-t-target","shared":1}],"records":[{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","tldr":"STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3."},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","tldr":"A relative of PSA that stays attached to prostate cancer cells, used as a T-cell engager address by J&J."},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","tldr":"A protein that appears on the surface of small-cell lung cancer cells, now hit by a drug that pulls T cells onto them."},{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/","tldr":"BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma."},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/","tldr":"GPRC5D is a second myeloma target used when BCMA-directed drugs stop working."},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/","tldr":"CD3 is the switch on every T cell. Bispecific drugs grab it with one arm and the tumour with the other, forcing the T cell to attack."}]}